Published in J Clin Endocrinol Metab on June 01, 2004
Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Arch (2007) 1.44
Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genet (2010) 1.09
Early and late events induced by polyQ-expanded proteins: identification of a common pathogenic property of polYQ-expanded proteins. J Biol Chem (2010) 0.97
Aldo keto reductase 1B7 and prostaglandin F2alpha are regulators of adrenal endocrine functions. PLoS One (2009) 0.95
Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS One (2012) 0.93
Regulation of aldo-keto reductases in human diseases. Front Pharmacol (2012) 0.84
Expression of Wnt and TGF-β pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness. Pathol Res Pract (2013) 0.83
Depressed levels of prostaglandin F2α in mice lacking Akr1b7 increase basal adiposity and predispose to diet-induced obesity. Diabetes (2012) 0.83
Aldo-Keto Reductases 1B in Endocrinology and Metabolism. Front Pharmacol (2012) 0.83
Transcriptional analysis of normal human fibroblast responses to microgravity stress. Genomics Proteomics Bioinformatics (2008) 0.83
Targeting aldose reductase for the treatment of cancer. Curr Cancer Drug Targets (2011) 0.81
mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). Hum Mol Genet (2014) 0.80
Molecular functions of thyroid hormones and their clinical significance in liver-related diseases. Biomed Res Int (2013) 0.80
Aldo-keto reductase 1b7, a novel marker for renin cells, is regulated by cyclic AMP signaling. Am J Physiol Regul Integr Comp Physiol (2015) 0.76
Aldo-Keto Reductases 1B in Adrenal Cortex Physiology. Front Endocrinol (Lausanne) (2016) 0.75
Double NF1 inactivation affects adrenocortical function in NF1Prx1 mice and a human patient. PLoS One (2015) 0.75
Cushing's syndrome. Lancet (2006) 5.19
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell (2013) 3.24
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet (2010) 3.07
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet (2006) 2.86
Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med (2013) 2.66
Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab (2009) 2.23
The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab (2009) 2.22
Bronchial carcinoid tumors causing Cushing's syndrome: more aggressive behavior and the need for early diagnosis. Ann Thorac Surg (2012) 2.19
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab (2007) 2.06
SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet (2008) 2.00
Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res (2005) 1.92
Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab (2004) 1.91
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab (2011) 1.86
Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res (2003) 1.82
Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. Hum Mutat (2010) 1.81
ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med (2013) 1.79
The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One (2009) 1.75
Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem (2004) 1.74
Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest (2003) 1.73
Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol (2009) 1.73
Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res (2006) 1.72
Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab (2006) 1.67
Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer (2007) 1.63
Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab (2002) 1.59
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab (2007) 1.53
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol (2012) 1.51
SF-1 a key player in the development and differentiation of steroidogenic tissues. Nucl Recept (2003) 1.50
18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol (2004) 1.47
Liver X receptors regulate adrenal cholesterol balance. J Clin Invest (2006) 1.45
Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors. Cancer Res (2008) 1.39
Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet (2010) 1.38
Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet (2011) 1.38
Large deletions of the PRKAR1A gene in Carney complex. Clin Cancer Res (2008) 1.36
A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. J Clin Endocrinol Metab (2006) 1.35
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res (2008) 1.31
Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 1.30
Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab (2006) 1.29
Differential regulation of the human adrenocorticotropin receptor [melanocortin-2 receptor (MC2R)] by human MC2R accessory protein isoforms alpha and beta in isogenic human embryonic kidney 293 cells. Mol Endocrinol (2007) 1.26
Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab (2008) 1.22
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol (2005) 1.21
Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. J Appl Physiol (1985) (2004) 1.21
Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J (2002) 1.18
β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res (2010) 1.17
The melanocortin system in Fugu: determination of POMC/AGRP/MCR gene repertoire and synteny, as well as pharmacology and anatomical distribution of the MCRs. Mol Biol Evol (2003) 1.16
WT1 maintains adrenal-gonadal primordium identity and marks a population of AGP-like progenitors within the adrenal gland. Dev Cell (2013) 1.16
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab (2009) 1.15
Wnt/β-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol (2011) 1.15
Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet (2003) 1.15
The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits. J Clin Endocrinol Metab (2009) 1.15
Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. Am J Hum Genet (2013) 1.14
Cushing's disease. Best Pract Res Clin Endocrinol Metab (2009) 1.14
Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res (2010) 1.14
Novel FGFR1 sequence variants in Kallmann syndrome, and genetic evidence that the FGFR1c isoform is required in olfactory bulb and palate morphogenesis. Hum Mutat (2007) 1.13
Angiotensin-II acute regulation of rapid response genes in human, bovine, and rat adrenocortical cells. J Mol Endocrinol (2007) 1.13
18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab (2009) 1.12
Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. Clin Endocrinol (Oxf) (2007) 1.11
Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res (2009) 1.11
Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab (2010) 1.11
Multiple roles of the nuclear receptors for oxysterols liver X receptor to maintain male fertility. Mol Endocrinol (2007) 1.10
Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genet (2010) 1.09
Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab (2010) 1.09
A thyroid nodule revealing a paraganglioma in a patient with a new germline mutation in the succinate dehydrogenase B gene. Eur J Endocrinol (2004) 1.07
WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum Mol Genet (2013) 1.05